Paradigm Biopharmaceuticals (ASX:PAR) is an Australian biotechnology company developing injectable pentosan polysulfate sodium (iPPS) for the treatment of osteoarthritis (OA). OA is a degenerative joint disease that affects millions of people worldwide, and there is currently no cure. Paradigm's operations are focused on the development and commercialisation of iPPS. The company is currently conducting Phase 3 clinical trials of iPPS for the treatment of knee OA, and it expects to submit regulatory applications for approval in 2024. Paradigm is also exploring the use of iPPS to treat other forms of OA, such as hip and shoulder OA.